Introduction: Dry mouth has been reported as a symptom of COVID-19. In this study, xerostomia (dry mouth) was reported in patients with COVID-19. Materials & methods: Dry mouth was assessed in hospitalized patients with COVID-19 daily until all of the dry mouth symptoms resolved. Results: Dry mouth appeared in 60% of cases 3–4 days before as prodromal symptom and in others, simultaneously or 1–2 days after the onset of other symptoms. In most cases, with starting the treatment, dry mouth gradually disappeared. Conclusion: Xerostomia in COVID-19 could occur before the common symptoms. Therefore, it could be hypothesized that it could be used for early diagnosis, quarantine and treatment. As a result, disease transmission might be prevented and the best treatment outcomes could be achieved.

Background: SARS-CoV-2, is followed by several manifestations, such as fever, cough, respiratory distress syndrome and mucocutaneous lesions such as papules, urticaria, vasculitic purpura and erythema multiform. Case: A 22-year old woman was diagnosed with COVID-19. Considering the skin and oral lesions, erythema multiform was suggested as the most likely diagnosis. Oral valaciclovir was administered. Discussion: Erythema multiforme were reported in some patients with COVID-19. Its pathophysiology is not yet completely understood, but it seems there is a lymphocyte-mediated hypersensitivity reaction to SARS-CoV-2 antigens presenting in the skin. Conclusion: Mucocutaneous and oral lesions might be the first manifestations of COVID-19. Therefore, during the pandemic, it is prudent to consider this virus as a differential diagnosis once we encounter oral ulceration.

No abstract

No abstract